RT Journal Article SR Electronic T1 A common TMPRSS2 variant protects against severe COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.04.21252931 DO 10.1101/2021.03.04.21252931 A1 David, Alessia A1 Parkinson, Nicholas A1 Peacock, Thomas P A1 Pairo-Castineira, Erola A1 Khanna, Tarun A1 Cobat, Aurelie A1 Tenesa, Albert A1 Sancho-Shimizu, Vanessa A1 , A1 , A1 Casanova, Jean-Laurent A1 Abel, Laurent A1 Barclay, Wendy S. A1 Baillie, J. Kenneth A1 Sternberg, Michael JE YR 2021 UL http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252931.abstract AB Infection with SARS-CoV-2 has a wide range of clinical presentations, from asymptomatic to life-threatening. Old age is the strongest factor associated with increased COVID19-related mortality, followed by sex and pre-existing conditions. The importance of genetic and immunological factors on COVID19 outcome is also starting to emerge, as demonstrated by population studies and the discovery of damaging variants in genes controlling type I IFN immunity and of autoantibodies that neutralize type I IFNs. The human protein transmembrane protease serine type 2 (TMPRSS2) plays a key role in SARS-CoV-2 infection, as it is required to activate the virus’ spike protein, facilitating entry into target cells. We focused on the only common TMPRSS2 non-synonymous variant predicted to be damaging (rs12329760), which has a minor allele frequency of ∼25% in the population. In a large population of SARS-CoV-2 positive patients, we show that this variant is associated with a reduced likelihood of developing severe COVID19 (OR 0.87, 95%CI:0.79-0.97, p=0.01). This association was stronger in homozygous individuals when compared to the general population (OR 0.65, 95%CI:0.50-0.84, p=1.3×10−3). We demonstrate in vitro that this variant, which causes the amino acid substitution valine to methionine, impacts the catalytic activity of TMPRSS2 and is less able to support SARS-CoV-2 spike-mediated entry into cells.TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID19. Further studies are needed to assess the expression of the TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID19. Clinical trials are needed to confirm this.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAD and NP were supported by the Wellcome Trust (grants 104955/Z/14/Z and 211496/Z/18/Z) and TK by the BBSRC (grants BB/P011705/1 and BB/P023959/1), VSS is supported by UKRI Future Leader Fellowship (MR/S032304/1), TPP and WSB are supported by BBSRC grants BB/R013071/1, AT was supported by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (references HDR-9004 and HDR-9003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics committees (Scotland 15/SS/0110, England, Wales and Northern Ireland: 19/WM/0247). Current and previous versions of the study protocol are available at genomicc.org/protocol. All participants gave informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary-level data in support of the findings of this study are available for download from [https://genomicc.org/data](https://genomicc.org/data). Individual level data can be analysed by qualified researchers in the ISARIC 4C/GenOMICC data analysis platform by application at [https://genomicc.org/data] (https://genomicc.org/data). BioBank data and Genomics England data are available to registered researchers at https://www.ukbiobank.ac.uk/ and https://www.genomicsengland.co.uk/. The COVID19 Host Genetics Initiative2 (COVID19hg) summary statistics are available at https://www.covid19hg.org/.